vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $158.6M, roughly 1.3× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 57.4%, a 13.8% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $131.7M).
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
IDYA vs STOK — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $158.6M |
| Net Profit | $119.2M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | 52.2% | 70.2% |
| Net Margin | 57.4% | 71.2% |
| Revenue YoY | — | 3661.1% |
| Net Profit YoY | 330.1% | 528.0% |
| EPS (diluted) | $1.33 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $207.8M | — | ||
| Q1 25 | — | $158.6M | ||
| Q4 24 | — | $22.6M | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $0 | — | ||
| Q2 23 | — | $-2.5M | ||
| Q3 22 | $29.7M | — |
| Q3 25 | $119.2M | — | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $-10.5M | ||
| Q3 24 | $-51.8M | — | ||
| Q2 24 | $-52.8M | — | ||
| Q1 24 | $-39.6M | — | ||
| Q2 23 | — | $-30.7M | ||
| Q3 22 | $1.6M | — |
| Q3 25 | 52.2% | — | ||
| Q1 25 | — | 70.2% | ||
| Q4 24 | — | -60.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q2 23 | — | 1340.7% | ||
| Q3 22 | 2.2% | — |
| Q3 25 | 57.4% | — | ||
| Q1 25 | — | 71.2% | ||
| Q4 24 | — | -46.4% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q2 23 | — | 1235.6% | ||
| Q3 22 | 5.4% | — |
| Q3 25 | $1.33 | — | ||
| Q1 25 | — | $1.90 | ||
| Q4 24 | — | $-0.15 | ||
| Q3 24 | $-0.60 | — | ||
| Q2 24 | $-0.68 | — | ||
| Q1 24 | $-0.53 | — | ||
| Q2 23 | — | $-0.69 | ||
| Q3 22 | $0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.1B | $350.1M |
| Total Assets | $1.2B | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $786.9M | — | ||
| Q1 25 | — | $274.8M | ||
| Q4 24 | — | $128.0M | ||
| Q3 24 | $920.0M | — | ||
| Q2 24 | $701.7M | — | ||
| Q1 24 | $698.8M | — | ||
| Q2 23 | — | $192.1M | ||
| Q3 22 | $386.2M | — |
| Q3 25 | $1.1B | — | ||
| Q1 25 | — | $350.1M | ||
| Q4 24 | — | $229.0M | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $931.7M | — | ||
| Q1 24 | $935.3M | — | ||
| Q2 23 | — | $190.2M | ||
| Q3 22 | $368.8M | — |
| Q3 25 | $1.2B | — | ||
| Q1 25 | — | $406.9M | ||
| Q4 24 | — | $271.6M | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $973.7M | — | ||
| Q1 24 | $961.5M | — | ||
| Q2 23 | — | $256.9M | ||
| Q3 22 | $410.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | $131.8M |
| Free Cash FlowOCF − Capex | $142.2M | $131.7M |
| FCF MarginFCF / Revenue | 68.4% | 83.0% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.19× | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $142.2M | — | ||
| Q1 25 | — | $131.8M | ||
| Q4 24 | — | $-23.2M | ||
| Q3 24 | $-49.2M | — | ||
| Q2 24 | $-32.9M | — | ||
| Q1 24 | $-43.8M | — | ||
| Q2 23 | — | $-21.8M | ||
| Q3 22 | $-24.2M | — |
| Q3 25 | $142.2M | — | ||
| Q1 25 | — | $131.7M | ||
| Q4 24 | — | $-23.2M | ||
| Q3 24 | $-49.7M | — | ||
| Q2 24 | $-33.9M | — | ||
| Q1 24 | $-45.1M | — | ||
| Q2 23 | — | $-22.6M | ||
| Q3 22 | $-25.3M | — |
| Q3 25 | 68.4% | — | ||
| Q1 25 | — | 83.0% | ||
| Q4 24 | — | -102.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q2 23 | — | 912.5% | ||
| Q3 22 | -85.1% | — |
| Q3 25 | 0.0% | — | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q2 23 | — | -33.8% | ||
| Q3 22 | 3.7% | — |
| Q3 25 | 1.19× | — | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q2 23 | — | — | ||
| Q3 22 | -14.96× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
